Monalizumab (IPH2201)

monalizumab · Innate Pharma

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Monalizumab (IPH2201), covering 2025-06-19 to 2025-06-19. Get the full timeline:

Most recent: Clinical Trial Update: Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial [Phase 1]

See pricing